A method for measurement of drug sensitivity of myeloma cells co-cultured with bone marrow stromal cells

Journal of Biomolecular Screening

Volumn 18, Issue 6, 2013, Pages 637-646

  Misund, Kristine ^a   Baranowska, Katarzyna A ^a   Holien, Toril ^a   Rampa, Christoph ^a   Klein, Dionne C G ^a   Børset, Magne ^a,b   Waage, Anders ^a,b   Sundan, Anders ^a  

^a NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^b TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

Author keywords

automated microscopy; bone marrow stromal cells; co culture; drug sensitivity; multiple myeloma

Indexed keywords

5' NUCLEOTIDASE; BETA1 INTEGRIN; BORTEZOMIB; ENDOGLIN; HERMES ANTIGEN; HLA ANTIGEN; INTERLEUKIN 6; SYNDECAN 1; THY 1 ANTIGEN;

APOPTOSIS; ARTICLE; BONE MARROW STROMA CELL; CELL COUNT; CELL CULTURE; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; DRUG SENSITIVITY; FLOW CYTOMETRY; FLUORESCENCE; FLUORESCENCE MICROSCOPY; IN VITRO STUDY; MULTIPLE MYELOMA; MYELOMA CELL; PRIORITY JOURNAL; STROMA CELL;

AUTOMATED MICROSCOPY; BONE MARROW STROMAL CELLS; CO-CULTURE; DRUG SENSITIVITY; MULTIPLE MYELOMA;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BENZOXAZOLES; CELL NUCLEOLUS; CELL SURVIVAL; COCULTURE TECHNIQUES; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; MESENCHYMAL STROMAL CELLS; MULTIPLE MYELOMA; QUINOLINIUM COMPOUNDS; TUMOR CELLS, CULTURED; TUMOR MICROENVIRONMENT;

EID: 84879474695     PISSN: 10870571     EISSN: 1552454X     Source Type: Journal    
DOI: 10.1177/1087057113478168     Document Type: Article

References (25)

1. Palumbo A., Anderson K.. Multiple Myeloma. N. Engl. J. Med. 2011 ; 364: 1046-1060
2. Mahindra A., Laubach J., Raje N., Munshi N., Richardson P. G., Anderson K.. Latest Advances and Current Challenges in the Treatment of Multiple Myeloma. Nat. Rev. Clin. Oncol. 2012 ; 9: 135-143
3. Cheung W. C., Van Ness B.. The Bone Marrow Stromal Microenvironment Influences Myeloma Therapeutic Response In Vitro. Leukemia. 2001 ; 15: 264-271
4. Noborio-Hatano K., Kikuchi J., Takatoku M., Shimizu R., Wada T., Ueda M., Nobuyoshi M., Oh I., Sato K., Suzuki T., Ozaki K., Mori M., Nagai T., Muroi K., Kano Y., Furukawa Y., Ozawa K.. Bortezomib Overcomes Cell-Adhesion-Mediated Drug Resistance through Downregulation of VLA-4 Expression in Multiple Myeloma. Oncogene. 2009 ; 28: 231-242
5. Perez L. E., Parquet N., Shain K., Nimmanapalli R., Alsina M., Anasetti C., Dalton W.. Bone Marrow Stroma Confers Resistance to Apo2 Ligand/TRAIL in Multiple Myeloma in Part by Regulating c-FLIP. J. Immunol. 2008 ; 180: 1545-1555
6. Meads M. B., Hazlehurst L. A., Dalton W. S.. The Bone Marrow Microenvironment as a Tumor Sanctuary and Contributor to Drug Resistance. Clin. Cancer Res. 2008 ; 14: 2519-2526
7. Nefedova Y., Landowski T. H., Dalton W. S.. Bone Marrow Stromal-Derived Soluble Factors and Direct Cell Contact Contribute to De Novo Drug Resistance of Myeloma Cells by Distinct Mechanisms. Leukemia. 2003 ; 17: 1175-1182
8. Barretina J., Caponigro G., Stransky N., Venkatesan K., Margolin A. A., Kim S., Wilson C. J., Lehar J., Kryukov G. V., Sonkin D., et al. The Cancer Cell Line Encyclopedia Enables Predictive Modelling of Anticancer Drug Sensitivity. Nature. 2012 ; 483: 603-607
9. Garnett M. J., Edelman E. J., Heidorn S. J., Greenman C. D., Dastur A., Lau K. W., Greninger P., Thompson I. R., Luo X., Soares J., et al. Systematic Identification of Genomic Markers of Drug Sensitivity in Cancer Cells. Nature. 2012 ; 483: 570-575
10. Ramasamy K., Khatun H., Macpherson L., Caley M. P., Sturge J., Mufti G. J., Schey S. A., Calle Y.. Fluorescence-Based Experimental Model to Evaluate the Concomitant Effect of Drugs on the Tumour Microenvironment and Cancer Cells. Br. J. Haematol. 2012 ; 157: 564-579
11. McMillin D. W., Delmore J., Weisberg E., Negri J. M., Geer D. C., Klippel S., Mitsiades N., Schlossman R. L., Munshi N. C., Kung A. L., et al. Tumor Cell-Specific Bioluminescence Platform to Identify Stroma-Induced Changes to Anticancer Drug Activity. Nat. Med. 2010 ; 16: 483-489
12. Holien T., Vatsveen T. K., Hella H., Waage A., Sundan A.. Addiction to c-MYC in Multiple Myeloma. Blood. 2012 ; 120: 2450-2453
13. Young E. W., Pak C., Kahl B. S., Yang D. T., Callander N. S., Miyamoto S., Beebe D. J.. Microscale Functional Cytomics for Studying Hematologic Cancers. Blood. 2012 ; 119: e76 - e85
14. Liebel U., Starkuviene V., Erfle H., Simpson J. C., Poustka A., Wiemann S., Pepperkok R.. A Microscope-Based Screening Platform for Large-Scale Functional Protein Analysis in Intact Cells. FEBS Lett. 2003 ; 554: 394-398
15. Jensen N. A., Gerth K., Grotjohann T., Kapp D., Keck M., Niehaus K.. Establishment of a High Content Assay for the Identification and Characterisation of Bioactivities in Crude Bacterial Extracts That Interfere with the Eukaryotic Cell Cycle. J. Biotechnol. 2009 ; 140: 124-134
16. Wlodkowic D., Telford W., Skommer J., Darzynkiewicz Z.. Apoptosis and Beyond: Cytometry in Studies of Programmed Cell Death. Methods Cell Biol. 2011 ; 103: 55-98
17. Jourdan M., Ferlin M., Legouffe E., Horvathova M., Liautard J., Rossi J. F., Wijdenes J., Brochier J., Klein B.. The Myeloma Cell Antigen Syndecan-1 Is Lost by Apoptotic Myeloma Cells. Br. J. Haematol. 1998 ; 100: 637-646
18. Chatterjee M., Honemann D., Lentzsch S., Bommert K., Sers C., Herrmann P., Mathas S., Dorken B., Bargou R. C.. In the Presence of Bone Marrow Stromal Cells Human Multiple Myeloma Cells Become Independent of the IL-6/gp130/STAT3 Pathway. Blood. 2002 ; 100: 3311-3318
19. Chapman M. A., Lawrence M. S., Keats J. J., Cibulskis K., Sougnez C., Schinzel A. C., Harview C. L., Brunet J. P., Ahmann G. J., Adli M., et al. Initial Genome Sequencing and Analysis of Multiple Myeloma. Nature. 2011 ; 471: 467-472
20. Egan J. B., Shi C. X., Tembe W., Christoforides A., Kurdoglu A., Sinari S., Middha S., Asmann Y., Schmidt J., Braggio E., et al. Whole Genome Sequencing of Multiple Myeloma from Diagnosis to Plasma Cell Leukemia Reveals Genomic Initiating Events, Evolution and Clonal Tides. Blood. 2012 ; 120: 1060-1066
21. Morgan G. J., Walker B. A., Davies F. E.. The Genetic Architecture of Multiple Myeloma. Nat. Rev. Cancer. 2012 ; 12: 335-348
22. Avet-Loiseau H., Magrangeas F., Moreau P., Attal M., Facon T., Anderson K., Harousseau J., N. M., S. M. Molecular Heterogeneity of Multiple Myeloma: Pathogenesis, Prognosis, and Therapeutic Implications. J. Clin. Oncol. 2011 ; 29: 1893-1897
23. Abe M., Hiura K., Wilde J., Shioyasono A., Moriyama K., Hashimoto T., Kido S., Oshima T., Shibata H., Ozaki S., et al. Osteoclasts Enhance Myeloma Cell Growth and Survival via Cell-Cell Contact: A Vicious Cycle between Bone Destruction and Myeloma Expansion. Blood. 2004 ; 104: 2484-2491
24. Kim J., Denu R. A., Dollar B. A., Escalante L. E., Kuether J. P., Callander N. S., Asimakopoulos F., Hematti P.. Macrophages and Mesenchymal Stromal Cells Support Survival and Proliferation of Multiple Myeloma Cells. Br. J. Haematol. 2012 ; 158: 336-346
25. Zheng Y., Cai Z., Wang S., Zhang X., Qian J., Hong S., Li H., Wang M., Yang J., Yi Q.. Macrophages are an Abundant Component of Myeloma Microenvironment and Protect Myeloma Cells from Chemotherapy Drug-Induced Apoptosis. Blood. 2009 ; 114: 3625-3628